ChemoCentryx Vasculitis Drug Hits Primary EndpointsANCA Vasculitis, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Clinical Trials, Complement Pathway, First-In-Class, Market Value, Neutrophils, R&D, Shares, Systemic DiseasesChemoCentryx and VFMCRP announced that the companies’ pivotal Phase III ADVOCATE clinical trial of avacopan for ANCA-associated vasculitis hit the study’s primary endpoints. Read more November 26, 2019/by BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png 0 0 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2019-11-26 12:18:282019-11-26 13:16:05ChemoCentryx Vasculitis Drug Hits Primary Endpoints
